From the Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (T.Z., P.W., H.S.).
Department of Physiology and Pharmacology, Loma Linda University, CA (T.Z., P.W., E.B., Q.Z., C.S., J.M., J.P., V.G., J.T., J.H.Z.).
Stroke. 2019 Apr;50(4):978-988. doi: 10.1161/STROKEAHA.118.021590.
Background and Purpose- Mitoquinone has been reported as a mitochondria-targeting antioxidant to promote mitophagy in various chronic diseases. Here, our aim was to study the role of mitoquinone in mitophagy activation and oxidative stress-induced neuronal death reduction after subarachnoid hemorrhage (SAH) in rats. Methods- Endovascular perforation was used for SAH model of male Sprague-Dawley rats. Exogenous mitoquinone was injected intraperitoneally 1 hour after SAH. ML385, an inhibitor of Nrf2 (nuclear factor-E2-related factor 2), was given intracerebroventricularly 24 hours before SAH. Small interfering RNA for PHB2 (prohibitin 2) was injected intracerebroventricularly 48 hours before SAH. Nuclear, mitochondrial, and cytoplasmic fractions were gathered using nucleus and mitochondria isolation kits. SAH grade evaluation, short- and long- term neurological function tests, oxidative stress, and apoptosis measurements were performed. Pathway related proteins were investigated with Western blot and immunofluorescence staining. Results- Expression of Keap1 (Kelch-like epichlorohydrin-associated protein 1, 2.84× at 24 hours), Nrf2 (2.78× at 3 hours), and LC3II (light chain 3-II; 1.94× at 24 hours) increased, whereas PHB2 (0.46× at 24 hours) decreased after SAH compared with sham group. Mitoquinone treatment attenuated oxidative stress and neuronal death, both short-term and long-term. Administration of mitoquinone resulted in a decrease in expression of Keap1 (0.33×), Romo1 (reactive oxygen species modulator 1; 0.24×), Bax (B-cell lymphoma-2 associated X protein; 0.31×), Cleaved Caspase-3 (0.29×) and an increase in Nrf2 (2.13×), Bcl-xl (B-cell lymphoma-extra large; 1.67×), PINK1 (phosphatase and tensin-induced kinase 1; 1.67×), Parkin (1.49×), PHB2 (1.60×), and LC3II (1.67×) proteins compared with SAH+vehicle group. ML385 abolished the treatment effects of mitoquinone on behavior and protein levels. PHB2 small interfering RNA reversed the outcomes of mitoquinone administration through reduction in protein expressions downstream of PHB2. Conclusions- Mitoquinone inhibited oxidative stress-related neuronal death by activating mitophagy via Keap1/Nrf2/PHB2 pathway after SAH. Mitoquinone may serve as a potential treatment to relieve brain injury after SAH.
背景与目的- 已报道线粒体靶向抗氧化剂米托醌可促进多种慢性疾病中的自噬。本研究旨在探讨米托醌在蛛网膜下腔出血(SAH)后大鼠自噬激活和氧化应激诱导的神经元死亡减少中的作用。方法- 采用血管内穿孔法制作雄性 Sprague-Dawley 大鼠的 SAH 模型。SAH 后 1 小时经腹腔注射外源性米托醌。SAH 前 24 小时经侧脑室给予 Nrf2(核因子-E2 相关因子 2)抑制剂 ML385。SAH 前 48 小时经侧脑室注射 PHB2(阻遏素 2)的小干扰 RNA。采用核和线粒体分离试剂盒收集核、线粒体和细胞质部分。进行 SAH 分级评估、短期和长期神经功能测试、氧化应激和细胞凋亡测定。采用 Western blot 和免疫荧光染色法检测相关通路蛋白。结果- 与假手术组相比,SAH 后 Keap1(Kelch-like epichlorohydrin-associated protein 1,24 小时时为 2.84×)、Nrf2(3 小时时为 2.78×)和 LC3II(轻链 3-II;24 小时时为 1.94×)的表达增加,而 PHB2(24 小时时为 0.46×)的表达减少。与 SAH+vehicle 组相比,米托醌治疗减轻了短期和长期的氧化应激和神经元死亡。米托醌治疗后 Keap1(0.33×)、Romo1(活性氧调节剂 1;0.24×)、Bax(B 细胞淋巴瘤-2 相关 X 蛋白;0.31×)、Cleaved Caspase-3(0.29×)的表达减少,而 Nrf2(2.13×)、Bcl-xl(B 细胞淋巴瘤-extra large;1.67×)、PINK1(磷酸酶和张力蛋白诱导激酶 1;1.67×)、Parkin(1.49×)、PHB2(1.60×)和 LC3II(1.67×)的表达增加。ML385 消除了米托醌对行为和蛋白水平的治疗作用。PHB2 小干扰 RNA 通过降低 PHB2 下游蛋白的表达逆转了米托醌给药的结果。结论- 米托醌通过 Keap1/Nrf2/PHB2 通路抑制氧化应激相关的神经元死亡,从而激活自噬,减轻蛛网膜下腔出血后的脑损伤。米托醌可能是一种缓解蛛网膜下腔出血后脑损伤的潜在治疗方法。
J Diabetes Investig. 2024-5
Oxid Med Cell Longev. 2022-2-24
Front Cell Neurosci. 2025-4-7
Neurochem Res. 2025-3-7
Pharmaceuticals (Basel). 2024-9-30
J Nanobiotechnology. 2024-10-18
Cell Mol Life Sci. 2017-10-30